186 related articles for article (PubMed ID: 19056257)
1. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
Chung SC; Hammarsten P; Josefsson A; Stattin P; Granfors T; Egevad L; Mancini G; Lutz B; Bergh A; Fowler CJ
Eur J Cancer; 2009 Jan; 45(1):174-82. PubMed ID: 19056257
[TBL] [Abstract][Full Text] [Related]
2. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4.
Thors L; Bergh A; Persson E; Hammarsten P; Stattin P; Egevad L; Granfors T; Fowler CJ
PLoS One; 2010 Aug; 5(8):e12275. PubMed ID: 20808855
[TBL] [Abstract][Full Text] [Related]
4. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
5. Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer.
Fowler CJ; Josefsson A; Thors L; Chung SC; Hammarsten P; Wikström P; Bergh A
Biochim Biophys Acta; 2013 Oct; 1831(10):1579-87. PubMed ID: 23262399
[TBL] [Abstract][Full Text] [Related]
6. Tumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer.
Fowler CJ; Hammarsten P; Bergh A
PLoS One; 2010 Dec; 5(12):e15205. PubMed ID: 21203460
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
8. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
[TBL] [Abstract][Full Text] [Related]
9. High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer.
Gustafsson SB; Palmqvist R; Henriksson ML; Dahlin AM; Edin S; Jacobsson SO; Öberg Å; Fowler CJ
PLoS One; 2011; 6(8):e23003. PubMed ID: 21901119
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
11. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
13. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma.
Väre P; Loikkanen I; Hirvikoski P; Vaarala MH; Soini Y
Oncol Rep; 2008 Jan; 19(1):25-31. PubMed ID: 18097572
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer.
Fujimura T; Takahashi S; Urano T; Ijichi N; Ikeda K; Kumagai J; Murata T; Takayama K; Horie-Inoue K; Ouchi Y; Muramatsu M; Homma Y; Inoue S
Cancer Sci; 2010 Mar; 101(3):646-51. PubMed ID: 20128821
[TBL] [Abstract][Full Text] [Related]
15. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
[TBL] [Abstract][Full Text] [Related]
16. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
Tsunoda T; Furusato B; Takashima Y; Ravulapalli S; Dobi A; Srivastava S; McLeod DG; Sesterhenn IA; Ornstein DK; Shirasawa S
Prostate; 2009 Sep; 69(13):1398-403. PubMed ID: 19479898
[TBL] [Abstract][Full Text] [Related]
17. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
Tidehag V; Hammarsten P; Egevad L; Granfors T; Stattin P; Leanderson T; Wikström P; Josefsson A; Hägglöf C; Bergh A
Eur J Cancer; 2014 Jul; 50(10):1829-1835. PubMed ID: 24726733
[TBL] [Abstract][Full Text] [Related]
18. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
[TBL] [Abstract][Full Text] [Related]
19. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
